DLL3 and small cell lung carcinoma: The results obtained from our study have significant relevance for the development of novel approaches aimed at determining SCLC's sensitivity to anticancer therapy, predicting overall survival, and designing rational combination cancer immunotherapies targeting PDL1 and DLL3 antigens.